The unexpected scrutiny from the FTC on a vertical merger has caught many off guard, especially given the rarity of such challenges in recent decades. During a recent visit to DC, it became clear that lawmakers were both impressed and confused about a groundbreaking cancer test that remains largely unknown to the public. There’s a strong push to expedite access to this life-saving test, particularly for underserved communities, as it currently exists only as a self-pay option costing nearly $1,000.
